Carcinoma, Bronchogenic clinical trials
The registry lists 66 studies for Carcinoma, Bronchogenic across more than 10 countries. 12 are recruiting or about to start. 16 of them are mainly about Carcinoma, Bronchogenic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-06. Counting its 2 narrower conditions too, such as Carcinoma, Non-Small-Cell Lung: 8,603 studies, 2,127 open.
Get an email when these change. Save the Carcinoma, Bronchogenic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
AstraZeneca (6) · Blueprint Medicines Corporation (4) · Hoffmann-La Roche (3) · Fundación GECP (3) · Eli Lilly and Company (3) · VA Office of Research and Development (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · University Hospital, Angers (2)
What is being tested here
Drugs under test in Carcinoma, Bronchogenic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Olomorasib | 1 | 1 | 1 |
| Osimertinib | 1 | 0 | 1 |
| Repotrectinib | 1 | 0 | 1 |
| Adebrelimab | 1 | 0 | 1 |
| Selpercatinib | 0 | 0 | 2 |
| Atezolizumab | 0 | 0 | 2 |
| Pralsetinib | 0 | 1 | 2 |
| Camrelizumab | 0 | 1 | 2 |
| Carboplatin | 0 | 1 | 2 |
| Pemetrexed | 0 | 1 | 2 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Immune checkpoint inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4, phase 3 first
- Dec 2026Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) · Phase 3 · Qilu Pharmaceutical Co., Ltd.
- Nov 2027A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer · Phase 3 · Eli Lilly and Company
- Dec 2026Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC · Weill Medical College of Cornell University
- Nov 2027Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study · AstraZeneca
Who these studies take
Of the 12 Carcinoma, Bronchogenic studies recruiting now, 11 (92%) set no upper age limit and 1 (8%) stop at 75 or younger. 2 (17%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (8%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (8%) | 1 (8%) |
| 18 | 12 (100%) | 12 (100%) |
| 30 | 12 (100%) | 12 (100%) |
| 40 | 12 (100%) | 12 (100%) |
| 50 | 12 (100%) | 12 (100%) |
| 65 | 12 (100%) | 12 (100%) |
| 75 | 12 (100%) | 12 (100%) |
| 85 | 11 (92%) | 11 (92%) |
Across all 66 studies, recruiting or not: 12% stop at 75 or younger and 2% at 65; 11% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
- Development of Clinical and Biological Database on Bronchial CancerNov 6, 2026NCT07085429
Studies
Recruiting first, then most recently updated. Showing 50 of 66. Browse all 66 → or search them.
- Development of Clinical and Biological Database on Bronchial CancerRecruitingNCT07085429Not applicable1 country
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 329 countries
- Veterans Affairs Lung Cancer Surgery Or Stereotactic RadiotherapyRecruitingNCT02984761Not applicable1 country
- Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingNCT07279935Phase 41 country
- Evaluation of Skin Tests in Biotherapy AllergiesRecruitingNCT06971848Not applicable1 country
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/219 countries
- Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerRecruitingNCT05297734Not applicable1 country
- Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLCRecruitingNCT06623656Phase 21 country
- EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid TumorsRecruitingNCT07410676Phase 1/21 country
- A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCRecruitingNCT06177925Phase 21 country
- LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)RecruitingNCT042282371 country
- Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During RadiotherapyRecruitingNCT04517019Not applicable1 country
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 313 countries
- Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyActive, not recruitingNCT064942411 country
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 21 country
- Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingNCT063760841 country
- Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)CompletedNCT04776447Phase 21 country
- A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 21 country
- Rehabilitation by Effort for Patients With Advanced Bronchial CancerTerminatedNCT03684486Not applicable1 country
- New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapyActive, not recruitingNCT04564157Phase 31 country
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/216 countries
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 322 countries
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/211 countries
- Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLCNo longer availableNCT06841874
- Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting (ImHADom)CompletedNCT037866531 country
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/213 countries
- Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsCompletedNCT04774952Phase 11 country
- Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsTerminatedNCT04512430Phase 21 country
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 110 countries
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 15 countries
- Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung CancerActive, not recruitingNCT065648701 country
- Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home SettingCompletedNCT048029021 country
- Stereotactic Margins in Localized Bronchial Cancer (T1/T2a, N0)CompletedNCT056052361 country
- Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung CancerCompletedNCT02904954Phase 21 country
- CAncer, NUtrition and Taste 2CompletedNCT05027490Not applicable1 country
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 21 country
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 11 country
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid TumorsStatus unknownNCT05886075Early Phase 11 country
- A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCStatus unknownNCT03085069Phase 21 country
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsStatus unknownNCT03634982Phase 11 country
- Effectiveness of Care in Certified Cancer Centres in GermanyCompletedNCT043342391 country
- Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerCompletedNCT01594398Phase 11 country
- Kinetics of Circulating Tumoral Cells in Bronchial Primitive CancerCompletedNCT03328559Not applicable1 country
- External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCStatus unknownNCT046974463 countries
- Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)CompletedNCT01999985Phase 11 country
- The EPIC Trial The Elderly Patient Individualized Chemotherapy TrialStatus unknownNCT03402048Phase 31 country
- A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCCompletedNCT03134872Phase 31 country
- Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung CancerCompletedNCT03331588Phase 31 country
- Tumour Registry Lung Cancer (TLK)CompletedNCT01192919
- Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)TerminatedNCT030532976 countries